Steven K. Albanese, PhD

Principal Scientist, Schrödinger, Inc in New York, NY

Steven K. Albanese, PhD

Principal Scientist, Schrödinger, Inc in New York, NY
Pictured: Steven Albanese

Start Year


End Year



Cornell University

My research interests fundamentally lie in drug development and cancer therapeutics. I am interested in applying computational approaches to improve the efficiency of the initial stages of development, as well as in understanding how point mutations can alter protein structure, which I believe can be exploited for the development of new and next-generation therapeutics. I chose Gerstner Sloan Kettering for graduate studies because it provides access to a phenomenal group of scientists and mentors — and because it was truly special to see how happy the graduate students were when I was interviewing! And New York City offers a huge number of opportunities. There is always something to do. If you have an interest, you can find something or somewhere to do it!


Lyczek A, Berger BT, Rangwala AM, Paung Y, Tom J, Philipose H, Guo J, Albanese SK, Robers MB, Knapp S, Chodera JD, Seeliger MA. (2021) Mutation in Abl kinase with altered drug-binding kinetics indicates a novel mechanism of imatinib resistance. Proc Natl Acad Scie USA.

Albanese SK, Chodera JD, Volkamer A, Keng S, Abel R, Wang L. (2020) Is Stucture-Based Drug Design Ready for Selectivity Optimization? J Chem Info Model. 2020 10, 1021.

Minuesa G, Albanese SK, Xie W, Kazansky Y, Worroll D, Chow A, Schurer A, Park SM, Rotsides CZ, Taggart J, Rizzi A, Naden LN, Chou T, Gourkanti S, Cappel D, Passarelli MC, Fairchild L, Adura C, Glickman JF, Schulman J, Famulare C, Patel M, Eibl JK, Ross GM, Bhattacharya S, Tan DS, Leslie CS, Beuming T, Patel DJ, Goldgur Y, Chodera JD, Kharas MG; (2019) Small-molecule targeting of MUSASHI RNA-binding activity in acute myeloid leukemia. Nat Commun. 10, 2691. PMCID:PMC6584500.

Hauser K, Negron C, Albanese SK, Ray S, Steinbrecher T, Abel R, Chodera JD, Wang L. (2018) Predicting resistance of clinical Abl mutations to targeted kinase inhibitors using alchemical free-energy calculations. Commun Biol 1, pii: 70. PMCID: PMC6110136

Albanese SK, Parton DL, Işık M, Rodríguez-Laureano L, Hanson SM, Behr JM, Gradia S, Jeans C, Levinson NM, Seeliger MA, Chodera JD; (2018) An Open Library of Human Kinase Domain Constructs for Automated Bacterial Expression. Biochemistry 57, 4675-4689. PMCID: PMC6081246 [Available on 2019-08-07].

Intlekofer AM, Shih AH, Wang B, Nazir A, Rustenburg AS, Albanese SK, Patel M, Famulare C, Correa FM, Takemoto N, Durani V, Liu H, Taylor J, Farnoud N, Papaemmanuil E, Cross JR, Tallman MS, Arcila ME, Roshal M, Petsko GA, Wu B, Choe S, Konteatis ZD, Biller SA, Chodera JD, Thompson CB, Levine RL, Stein EM. (2018) Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations. Nature 559, 125-129.

Ruff EF, Muretta JM, Thompson AR, Lake EW, Cyphers S, Albanese SK, Hanson SM, Behr JM, Thomas DD, Chodera JD, Levinson NM. (2018) A dynamic mechanism for allosteric activation of Aurora kinase A by activation loop phosphorylation. Elife 7, e32766.

Xu J, Pham CG, Albanese SK, Dong Y, Oyama T, Lee CH, Rodrik-Outmezguine V, Yao Z, Han S, Chen D, Parton DL, Chodera JD, Rosen N, Cheng EH, Hsieh JJ. (2016) Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin. J Clin Invest, pii: 86120.

View a full listing of Steven K. Albanese’s journal articles.